DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Cyclophosphamide (Cyclophosphamide) - Infection - Suspected Cause - Side Effect Reports

 
 



Index of reports > Cases with Infection (257)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Cyclophosphamide where reactions include infection. The selected reports were submitted to the FDA during the sample period of about a year.

 Reports 1 - 30 of 257   Next >>

Possible Cyclophosphamide side effects in 49 year old male

Reported by a physician from Norway on 2012-08-27

Patient: 49 year old male

Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Septic Shock, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Bleomycin Sulfate
    Dosage: 10000 iu, day 8 (2 escalated cycles)
    Indication: Hodgkin's Disease

Bleomycin Sulfate
    Dosage: 10000 iu, day 8 (4 standard cycles)

Cyclophosphamide
    Dosage: 650 mg/m2, day 1 (4 standard cycles)

Cyclophosphamide
    Dosage: 1250 mg/m2, day 1 (2 escalated cycles)
    Indication: Hodgkin's Disease

Doxorubicin HCL
    Dosage: 25 mg/m2, day 1 (4 standard cycles)

Doxorubicin HCL
    Dosage: 35 mg/m2, day 1 (2 escalated cycles)
    Indication: Hodgkin's Disease

Etoposide
    Dosage: 100 mg/m2, day 1-3 (4 standard cycles)

Etoposide
    Dosage: 200 mg/m2, day 1-3 (2 escalated cycles)
    Indication: Hodgkin's Disease

Prednisolone
    Dosage: 40 mg/m2, day 1-14 (4 standard cycles)
    Administration route: Oral

Prednisolone
    Dosage: 40 mg/m2, day 1-14 (2 escalated cycles)
    Administration route: Oral
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Dosage: 100 mg/m2, day 1-7 (2 escalated cycles)
    Administration route: Oral
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Dosage: 100 mg/m2, day 1-7 (4 standard cycles)
    Administration route: Oral

Vincristine
    Dosage: 1.4 mg/m2, day 8 (2 escalated cycles)
    Indication: Hodgkin's Disease

Vincristine
    Dosage: 1.4 mg/m2, day 8 (4 standard cycles)



Possible Cyclophosphamide side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-27

Patient:

Reactions: Off Label Use, Gastrointestinal Toxicity, Neutropenia, Infection

Drug(s) suspected as cause:
Carboplatin
    Dosage: 6 courses in high risk
    Indication: Retinoblastoma

Cyclophosphamide
    Indication: Retinoblastoma

Doxorubicin Hydrochloride
    Dosage: 4 courses in intermediate risk and 6 courses in high risk
    Indication: Retinoblastoma

Etoposide
    Indication: Retinoblastoma

Vincristine
    Dosage: 4 courses in intermediate risk and 6 courses in high risk
    Indication: Retinoblastoma

Other drugs received by patient: Neupogen



Possible Cyclophosphamide side effects in 49 year old male

Reported by a physician from Norway on 2012-08-27

Patient: 49 year old male

Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Pyrexia, Lung Infiltration, Septic Shock, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Bleomycin Sulfate
    Dosage: on day 8
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: for escalated cycles on day 1
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: for standard cycles on day 1

Doxorubicin Hydrochloride
    Dosage: for escalated cycles on day 1
    Indication: Hodgkin's Disease

Doxorubicin Hydrochloride
    Dosage: on day 1,for standard cycles

Etoposide
    Dosage: for the escalated cycles on day 1 to 3

Etoposide
    Dosage: for the escalated cycles on day 1 to 3

Etoposide
    Dosage: for the standard cycles, day 1 to 3
    Indication: Hodgkin's Disease

Prednisolone
    Dosage: on day 1 to 14 every 21 day cycle treatment for 6 cycles
    Administration route: Oral
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Dosage: day 1 to 7
    Administration route: Oral
    Indication: Hodgkin's Disease

Vincristine
    Dosage: on day 8
    Indication: Hodgkin's Disease



Possible Cyclophosphamide side effects in 49 year old male

Reported by a physician from Norway on 2012-08-24

Patient: 49 year old male

Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Pyrexia, Lung Infiltration, Septic Shock, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Bleomycin Sulfate
    Dosage: on day 8
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: for escalated cycles on day 1
    Indication: Hodgkin's Disease

Cyclophosphamide
    Dosage: for standard cycles on day 1

Doxorubicin Hydrochloride
    Dosage: on day 1,for standard cycles

Doxorubicin Hydrochloride
    Dosage: for escalated cycles on day 1
    Indication: Hodgkin's Disease

Etoposide
    Dosage: for the escalated cycles on day 1 to 3

Etoposide
    Dosage: for the escalated cycles on day 1 to 3

Etoposide
    Dosage: for the standard cycles, day 1 to 3
    Indication: Hodgkin's Disease

Prednisolone
    Dosage: on day 1 to 14 every 21 day cycle treatment for 6 cycles
    Administration route: Oral
    Indication: Hodgkin's Disease

Procarbazine Hydrochloride
    Dosage: day 1 to 7
    Administration route: Oral
    Indication: Hodgkin's Disease

Vincristine
    Dosage: on day 8
    Indication: Hodgkin's Disease



Possible Cyclophosphamide side effects in male

Reported by a consumer/non-health professional from United States on 2012-08-23

Patient: male, weighing 79.0 kg (173.8 pounds)

Reactions: Phlebitis, Hydronephrosis, Adenovirus Infection, Cystitis Haemorrhagic, Human Polyomavirus Infection, Infection

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Campath
    Dosage: 30 mg/m2, on first 3 days of each cycle (total 6 cycles)
    Indication: Chronic Lymphocytic Leukaemia
    Start date: 2008-07-15
    End date: 2008-12-03

Cyclophosphamide
    Dosage: 500 mg/m2, on first 3 days of each cycle (total 6 cycles)
    Administration route: Oral
    Indication: Chronic Lymphocytic Leukaemia
    Start date: 2008-07-15
    End date: 2008-12-03

Fludara
    Dosage: 80 mg/m2, on first 3 days of each cycle (total 6 cycles)
    Administration route: Oral
    Indication: Chronic Lymphocytic Leukaemia
    Start date: 2008-07-15
    End date: 2008-12-03

Other drugs received by patient: Folic Acid; Bactrim; Vfend; Valganciclovir



Possible Cyclophosphamide side effects in male

Reported by a physician from United States on 2012-08-22

Patient: male

Reactions: Rectal Haemorrhage, Constipation, Cardiac Disorder, Hospitalisation, Granulocytopenia, Inappropriate Antidiuretic Hormone Secretion, Thrombocytopenia, Cardiac Failure Congestive, Pneumonia, Anaemia, Pancytopenia, Atrial Fibrillation, Febrile Neutropenia, Syncope, Embolism, Sepsis, Dehydration, Asthenia, Mantle Cell Lymphoma Recurrent, Leukopenia, Deep Vein Thrombosis, Infection

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on day 1
    Indication: Mantle Cell Lymphoma

Cyclophosphamide
    Dosage: on day 1
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1
    Indication: Mantle Cell Lymphoma

Leukine
    Dosage: on day 9-15; 250 mcg/m2/day
    Indication: Mantle Cell Lymphoma

Leukine
    Dosage: on day 9-15; 250 mcg/m2/day
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Indication: Mantle Cell Lymphoma

Prednisone TAB
    Dosage: on days 1-5
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Dosage: on day 15; as infusion
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Dosage: on day 15; as infusion
    Indication: Mantle Cell Lymphoma

Vincristine
    Dosage: on day 1 (maximum dose: 2mg)
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Dosage: on day 1 (maximum dose: 2mg)
    Indication: Mantle Cell Lymphoma



Possible Cyclophosphamide side effects in 56 year old female

Reported by a physician from United States on 2012-08-22

Patient: 56 year old female, weighing 91.2 kg (200.6 pounds)

Reactions: Anaemia, Infection

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Breast Cancer
    Start date: 2010-11-10
    End date: 2011-01-12

Doxorubicin Hydrochloride
    Dosage: 60mgm2 cyclic
    Indication: Breast Cancer
    Start date: 2010-11-10
    End date: 2011-01-12

Paclitaxel
    Dosage: 65mgm2 cyclic
    Indication: Breast Cancer
    Start date: 2011-02-03
    End date: 2011-04-13

Pazopanib
    Dosage: 400mg per day
    Administration route: Oral
    Indication: Breast Cancer
    Start date: 2011-02-03
    End date: 2011-04-10

Other drugs received by patient: Armodafinil



Possible Cyclophosphamide side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-21

Patient:

Reactions: Off Label Use, Gastrointestinal Toxicity, Neutropenia, Infection

Drug(s) suspected as cause:
Carboplatin
    Dosage: 6 courses in high risk
    Indication: Retinoblastoma

Cyclophosphamide
    Indication: Retinoblastoma

Doxorubicin HCL
    Dosage: 4 courses in intermediate risk and 6 courses in high risk
    Indication: Retinoblastoma

Etoposide
    Indication: Retinoblastoma

Vincristine
    Dosage: 4 courses in intermediate risk and 6 courses in high risk
    Indication: Retinoblastoma

Other drugs received by patient: Neupogen



Possible Cyclophosphamide side effects in

Reported by a physician from Germany on 2012-08-20

Patient:

Reactions: Infection

Adverse event resulted in: death, life threatening event, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: unk
    Indication: Multiple Myeloma
    Start date: 2012-03-26
    End date: 2012-07-05

Dexamethasone
    Dosage: unk
    Indication: Multiple Myeloma
    Start date: 2012-03-26
    End date: 2012-07-05

Velcade
    Dosage: unk
    Indication: Multiple Myeloma
    Start date: 2012-03-26
    End date: 2012-07-05

Other drugs received by patient: Zometa; Amoxicillin



Possible Cyclophosphamide side effects in male

Reported by a health professional (non-physician/pharmacist) from France on 2012-08-20

Patient: male

Reactions: Neutropenia, Infection

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Start date: 2012-05-21
    End date: 2012-05-21

Cyclophosphamide
    Start date: 2012-07-02
    End date: 2012-07-02

Cyclophosphamide
    Start date: 2012-07-23
    End date: 2012-07-23

Cyclophosphamide
    Start date: 2012-06-11
    End date: 2012-06-11

Doxorubicin Hydrochloride
    Start date: 2012-05-21
    End date: 2012-05-21

Doxorubicin Hydrochloride
    Start date: 2012-06-11
    End date: 2012-06-11

Doxorubicin Hydrochloride
    Start date: 2012-07-23
    End date: 2012-07-23

Doxorubicin Hydrochloride
    Start date: 2012-07-02
    End date: 2012-07-02

Etopophos Preservative Free
    Start date: 2012-06-11
    End date: 2012-06-11

Etopophos Preservative Free
    Start date: 2012-07-02
    End date: 2012-07-02

Etopophos Preservative Free
    Start date: 2012-07-23
    End date: 2012-07-23

Etopophos Preservative Free
    Start date: 2012-05-21
    End date: 2012-05-21

Mabthera
    Start date: 2012-05-21
    End date: 2012-05-21

Mabthera
    Start date: 2012-07-02
    End date: 2012-07-02

Mabthera
    Start date: 2012-06-11
    End date: 2012-06-11

Mabthera
    Start date: 2012-07-23
    End date: 2012-07-23

Other drugs received by patient: Acetaminophen; Lovenox; Nexium; Crestor; Clopidogrel Bisulfate and Aspirin; Valacyclovir Hydrochloride; Acebutolol



Possible Cyclophosphamide side effects in male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-17

Patient: male, weighing 79.0 kg (173.8 pounds)

Reactions: Cystitis Haemorrhagic, Adenovirus Infection, Human Polyomavirus Infection, Infection

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Campath
    Dosage: 30 mg/m2, 3 times per 1 cycle
    Indication: Chronic Lymphocytic Leukaemia
    Start date: 2008-07-15
    End date: 2008-12-03

Cyclophosphamide
    Dosage: 500 mg/m2, unk
    Administration route: Oral
    Indication: Chronic Lymphocytic Leukaemia
    Start date: 2008-07-15
    End date: 2008-12-03

Fludara
    Dosage: 80 mg/m2, unk
    Administration route: Oral
    Indication: Chronic Lymphocytic Leukaemia
    Start date: 2008-07-15
    End date: 2008-12-03

Other drugs received by patient: Vfend; Bactrim; Valganciclovir; Folic Acid



Possible Cyclophosphamide side effects in

Reported by a health professional (non-physician/pharmacist) from Denmark on 2012-08-14

Patient:

Reactions: Transplant Failure, Cardiac Failure, Myelodysplastic Syndrome, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Carmustine
    Indication: Mantle Cell Lymphoma

Cyclophosphamide
    Indication: Mantle Cell Lymphoma

Cytarabine
    Indication: Mantle Cell Lymphoma

Doxorubicin HCL
    Indication: Mantle Cell Lymphoma

Etoposide
    Indication: Mantle Cell Lymphoma

Mabthera
    Indication: Mantle Cell Lymphoma

Melphalan Hydrochloride
    Indication: Mantle Cell Lymphoma

Prednisolone
    Indication: Mantle Cell Lymphoma

Vincristine
    Indication: Mantle Cell Lymphoma



Possible Cyclophosphamide side effects in

Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-08-13

Patient:

Reactions: Pulmonary Embolism, Multiple Myeloma, Peripheral Sensory Neuropathy, Constipation, Somnolence, Death, Complications of Transplant Surgery, Peripheral Motor Neuropathy, Thrombosis in Device, Blood Alkaline Phosphatase Increased, Pancytopenia, Multiple Fractures, Rash, Renal Failure, Osteonecrosis of JAW, Embolism, Hypothyroidism, Deep Vein Thrombosis, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Multiple Myeloma

Dexamethasone
    Dosage: 40 milligram
    Administration route: Oral

Dexamethasone
    Dosage: 20 milligram
    Indication: Multiple Myeloma

Thalidomide
    Dosage: or 4 weeks and increased every 4 weeks in 50-mg increments to a maximum of 200mg/day
    Administration route: Oral
    Indication: Multiple Myeloma

Other drugs received by patient: Melphalan Hydrochloride; Prednisolone; CLO; ZOL; Melphalan Hydrochloride; Biphosphonate; Vincristine; Doxorubicin Hydrochloride; Bortezomib



Possible Cyclophosphamide side effects in

Reported by a health professional (non-physician/pharmacist) from Canada on 2012-08-09

Patient:

Reactions: Dermatitis Allergic, Pneumonia, Angina Pectoris, Febrile Neutropenia, Cognitive Disorder, Hepatitis, Arrhythmia, Interstitial Lung Disease, Gastrointestinal Disorder, Progressive Multifocal Leukoencephalopathy, Cardiac Failure Congestive, Infection

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin Hydrochloride
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone TAB
    Indication: Diffuse Large B-Cell Lymphoma

Radiotherapy
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Indication: Diffuse Large B-Cell Lymphoma



Possible Cyclophosphamide side effects in

Reported by a physician from Spain on 2012-08-06

Patient:

Reactions: Skin Toxicity, Sudden Death, Hepatic Failure, Encephalitis, Cytomegalovirus Colitis, Pneumonia Pneumococcal, Neurotoxicity, Death, Multi-Organ Failure, Metastasis, Cardiotoxicity, AIDS Dementia Complex, Pseudomonas Infection, Toxicity To Various Agents, Staphylococcal Infection, Pneumonia Herpes Viral, Neutropenia, Escherichia Infection, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: given on day 1 of the 3 week cycle
    Indication: Lymphoma AIDS Related

Doxorubicin HCL
    Dosage: given on day 1 of the 3 week cycle
    Indication: Lymphoma AIDS Related

Mabthera
    Dosage: given on day 1 of every 3 week cycle (prior to chop)
    Indication: Lymphoma AIDS Related

Prednisone TAB
    Dosage: given for 5 days
    Administration route: Oral
    Indication: Lymphoma AIDS Related

Vincristine Sulfate
    Dosage: given on day 1 of 3 week cycle.
    Indication: Lymphoma AIDS Related

Other drugs received by patient: Hydrocortisone; Cytarabine; Methotrexate



Possible Cyclophosphamide side effects in

Reported by a physician from Denmark on 2012-08-06

Patient:

Reactions: Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Carmustine
    Dosage: on day 1; beam/c
    Indication: Mantle Cell Lymphoma

Cyclophosphamide
    Dosage: day 1; cycle 5; chop regimen
    Indication: Mantle Cell Lymphoma

Cyclophosphamide
    Dosage: day 1; cycle 1; chop regimen

Cyclophosphamide
    Dosage: day 2-5 in beac regimen

Cyclophosphamide
    Dosage: day 1; cycle 3; chop regimen

Cytarabine
    Dosage: 3 or 2 g/m2, four-3 hour infusions; cycle 4
    Indication: Mantle Cell Lymphoma

Cytarabine
    Dosage: 3 or 2 g/m2, four-3 hour infusions; cycle 2

Cytarabine
    Dosage: day 2-5 in beam or beac regimen

Cytarabine
    Dosage: 3 or 2 g/m2, four-3 hour infusions; cycle 6

Doxorubicin HCL
    Dosage: on day 1; cycle 3
    Indication: Mantle Cell Lymphoma

Doxorubicin HCL
    Dosage: on day 1; cycle 1

Doxorubicin HCL
    Dosage: on day 1; cycle 5

Etoposide
    Dosage: day 2- 5; beam/c regimen
    Indication: Mantle Cell Lymphoma

Melphalan Hydrochloride
    Dosage: on day 6; beam regimen
    Indication: Mantle Cell Lymphoma

Prednisolone
    Dosage: on day 1-5; cycle 1

Prednisolone
    Dosage: on day 1-5; cycle 3

Prednisolone
    Dosage: on day 1-5; cycle 5
    Indication: Mantle Cell Lymphoma

Rituximab
    Dosage: day 1 cycle 5

Rituximab
    Dosage: day1 cycle 6, also given on day 9 for in-vivo purging

Rituximab
    Dosage: day 1 from cycle 4
    Indication: Mantle Cell Lymphoma

Vincristine
    Dosage: on day 1 ; cycle 5

Vincristine
    Dosage: on day 1; cycle 1
    Indication: Mantle Cell Lymphoma

Vincristine
    Dosage: on day 1; cycle 3



Possible Cyclophosphamide side effects in 76 year old

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-02

Patient: 76 year old

Reactions: Lung Disorder, Neutropenia, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Diffuse Large B-Cell Lymphoma

Doxorubicin Hydrochloride
    Indication: Diffuse Large B-Cell Lymphoma

Prednisone
    Dosage: daily for 5 days
    Indication: Diffuse Large B-Cell Lymphoma

Radiotherapy
    Indication: Diffuse Large B-Cell Lymphoma

Rituximab
    Indication: Diffuse Large B-Cell Lymphoma

Vincristine
    Indication: Diffuse Large B-Cell Lymphoma

Other drugs received by patient: Neupogen



Possible Cyclophosphamide side effects in

Reported by a physician from United Kingdom on 2012-08-01

Patient:

Reactions: Neutropenia, Infection

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1440 mg, unk
    Indication: Mantle Cell Lymphoma

Doxorubicin Hydrochloride
    Dosage: 96 mg, unk
    Indication: Mantle Cell Lymphoma

Prednisone
    Dosage: 100 mg, unk
    Indication: Mantle Cell Lymphoma

Prednisone
    Dosage: 80 unk, unk

Velcade
    Dosage: 3 mg, unk
    Indication: Mantle Cell Lymphoma
    Start date: 2011-01-27

Vincristine
    Indication: Mantle Cell Lymphoma

Other drugs received by patient: Sando K / 00031402 /



Possible Cyclophosphamide side effects in

Reported by a physician from United Kingdom on 2012-07-25

Patient:

Reactions: Neutropenia, Infection

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1440 mg, unk
    Indication: Mantle Cell Lymphoma

Doxorubicin Hydrochloride
    Dosage: 96 mg, unk
    Indication: Mantle Cell Lymphoma

Prednisone
    Dosage: 80 unk, unk

Prednisone
    Dosage: 100 mg, unk
    Indication: Mantle Cell Lymphoma

Velcade
    Dosage: 3 mg, unk
    Indication: Mantle Cell Lymphoma
    Start date: 2011-01-27

Vincristine
    Indication: Mantle Cell Lymphoma

Other drugs received by patient: Sando K / 00031402 /



Possible Cyclophosphamide side effects in

Reported by a physician from United States on 2012-07-23

Patient:

Reactions: Drug Ineffective, B-Cell Lymphoma, Palmar-Plantar Erythrodysaesthesia Syndrome, Device Related Infection, Upper Respiratory Tract Infection, Nervous System Disorder, Adverse Event, Lymphoma, Diffuse Large B-Cell Lymphoma, Mucosal Infection, Lymphoma AIDS Related, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Lymphoma AIDS Related

Doxorubicin Hydrochloride
    Dosage: on day 1
    Indication: Lymphoma AIDS Related

Prednisone
    Dosage: on days 1-5
    Administration route: Oral
    Indication: Lymphoma AIDS Related

Rituximab
    Indication: Lymphoma AIDS Related

Vincristine
    Dosage: not more than 2mg
    Indication: Lymphoma AIDS Related

Other drugs received by patient: Antiretroviral Medications; Neupogen; Quinolone; Unknown Medication; Neupogen; Unknown Medication; Pegfilgrastim



Possible Cyclophosphamide side effects in

Reported by a physician from United Kingdom on 2012-07-19

Patient:

Reactions: Neutropenia, Infection

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 1440 mg, unk
    Indication: Mantle Cell Lymphoma

Doxorubicin HCL
    Dosage: 96 mg, unk
    Indication: Mantle Cell Lymphoma

Prednisone
    Dosage: 100 mg, unk
    Indication: Mantle Cell Lymphoma

Prednisone
    Dosage: 80 unk, unk

Velcade
    Dosage: 3 mg, unk
    Indication: Mantle Cell Lymphoma
    Start date: 2011-01-27

Vincristine
    Indication: Mantle Cell Lymphoma

Other drugs received by patient: Sando K / 00031402 /



Possible Cyclophosphamide side effects in 39 year old female

Reported by a physician from United States on 2012-07-18

Patient: 39 year old female, weighing 88.8 kg (195.4 pounds)

Reactions: Dermatitis, Infection

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: 600mgm2 cyclic
    Indication: Breast Cancer
    Start date: 2011-02-24
    End date: 2011-05-05

Doxorubicin HCL
    Dosage: 60mgm2 cyclic
    Indication: Breast Cancer
    Start date: 2011-02-24
    End date: 2011-05-05

Paclitaxel
    Dosage: 80mgm2 cyclic
    Indication: Breast Cancer
    Start date: 2011-05-26
    End date: 2011-09-01

Pazopanib
    Dosage: 400mg per day
    Administration route: Oral
    Indication: Breast Cancer
    Start date: 2011-11-09
    End date: 2012-02-27

Radiation
    Indication: Breast Cancer
    Start date: 2011-11-16
    End date: 2011-12-21

Other drugs received by patient: Tamoxifen Citrate; Silvadene; Aquaphor; Lisinopril; Norvasc; Santyl



Possible Cyclophosphamide side effects in

Reported by a physician from Japan on 2012-07-17

Patient:

Reactions: Neuropathy Peripheral, Interstitial Lung Disease, Neutropenia, Infection

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Indication: B-Cell Lymphoma

Neupogen
    Indication: B-Cell Lymphoma

Prednisolone
    Indication: B-Cell Lymphoma

Rituxan
    Dosage: 6 doses-2 days prior to each cycle of chop
    Indication: B-Cell Lymphoma

Vincristine
    Indication: B-Cell Lymphoma



Possible Cyclophosphamide side effects in

Reported by a physician from United Kingdom on 2012-07-17

Patient:

Reactions: Abdominal Pain, Tachycardia, Skin Toxicity, Pyrexia, Fatigue, Neuropathy Peripheral, Hepatotoxicity, Adverse Event, Dizziness, Oedema, Hallucination, Vomiting, Nausea, Gastrointestinal Toxicity, Neutropenic Sepsis, Nephropathy Toxic, Hypotension, Condition Aggravated, Adult T-Cell Lymphoma / Leukaemia, Mucosal Inflammation, Lung Disorder, Infection, Infusion Related Reaction

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on day 1 of 21 day cycle, (cycle 1-5)
    Indication: Adult T-Cell Lymphoma / Leukaemia

Cytarabine
    Indication: Adult T-Cell Lymphoma / Leukaemia

Doxorubicin HCL
    Dosage: on day 1 of 21 day, (cycle 1-5)

Doxorubicin HCL
    Dosage: on day 1 of 21 day, (cycle 1-5)
    Indication: Adult T-Cell Lymphoma / Leukaemia

Hydrocortisone
    Indication: Adult T-Cell Lymphoma / Leukaemia

Methotrexate
    Indication: Adult T-Cell Lymphoma / Leukaemia

Prednisolone
    Dosage: on days 1-5 of 21 day cycle, (cycle 1-5)
    Administration route: Oral
    Indication: Adult T-Cell Lymphoma / Leukaemia

Radiotherapy
    Indication: Adult T-Cell Lymphoma / Leukaemia

Vincristine
    Dosage: (maximum 2 mg) on day 1 of 21 day cycle, (cycle 1-5)
    Indication: Adult T-Cell Lymphoma / Leukaemia

Zenapax
    Dosage: on days 7 and 14 on cycle 1 of 21 day cycle
    Indication: Adult T-Cell Lymphoma / Leukaemia

Other drugs received by patient: Acyclovir; Thiabendazole; Cotrim; Itraconazole



Possible Cyclophosphamide side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-16

Patient:

Reactions: B-Cell Lymphoma, Myelodysplastic Syndrome, Neutropenia, Infection

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Chronic Lymphocytic Leukaemia

Fludarabine Phosphate
    Indication: Chronic Lymphocytic Leukaemia

Mabthera
    Indication: Chronic Lymphocytic Leukaemia



Possible Cyclophosphamide side effects in

Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-07-13

Patient:

Reactions: Neuropathy Peripheral, Neutropenia, Infection, Infusion Related Reaction

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Dosage: 6-821 day cycles; n=28
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Dosage: 6-821 day cycles; n=28

Obinutuzumab
    Indication: B-Cell Lymphoma

Prednisone
    Indication: B-Cell Lymphoma

Vincristine
    Indication: B-Cell Lymphoma



Possible Cyclophosphamide side effects in

Reported by a individual with unspecified qualification from Croatia (Local Name: Hrvatska) on 2012-07-13

Patient:

Reactions: Mucosal Inflammation, Multi-Organ Failure, Tumour Lysis Syndrome, Febrile Neutropenia, Infection

Adverse event resulted in: death, hospitalization

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: Burkitt's Lymphoma

Cytarabine
    Indication: Burkitt's Lymphoma

Dexamethasone
    Indication: Burkitt's Lymphoma

Doxorubicin Hydrochloride
    Indication: Burkitt's Lymphoma

Etoposide
    Indication: Burkitt's Lymphoma

Ifosfamide
    Indication: Burkitt's Lymphoma

Mabthera
    Indication: Burkitt's Lymphoma

Methotrexate
    Indication: Burkitt's Lymphoma

Methylprednisolone
    Indication: Prophylaxis

Prednisone
    Indication: Burkitt's Lymphoma

Vincristine
    Indication: Burkitt's Lymphoma



Possible Cyclophosphamide side effects in

Reported by a physician from United Kingdom on 2012-07-10

Patient:

Reactions: Abdominal Pain, Skin Toxicity, Tachycardia, Pyrexia, Fatigue, Neuropathy Peripheral, Hepatotoxicity, Adverse Event, Oedema, Dizziness, Hallucination, Vomiting, Gastrointestinal Toxicity, Nausea, Neutropenic Sepsis, Nephropathy Toxic, Hypotension, Adult T-Cell Lymphoma / Leukaemia, Condition Aggravated, Mucosal Inflammation, Lung Disorder, Infection, Infusion Related Reaction

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: on day 1 of 21 day cycle, (cycle 1-5)
    Indication: Adult T-Cell Lymphoma / Leukaemia

Cytarabine
    Indication: Adult T-Cell Lymphoma / Leukaemia

Doxorubicin HCL
    Dosage: on day 1 of 21 day, (cycle 1-5)
    Indication: Adult T-Cell Lymphoma / Leukaemia

Hydrocortisone
    Indication: Adult T-Cell Lymphoma / Leukaemia

Methotrexate
    Indication: Adult T-Cell Lymphoma / Leukaemia

Prednisolone
    Dosage: on days 1-5 of 21 day cycle, (cycle 1-5)
    Administration route: Oral
    Indication: Adult T-Cell Lymphoma / Leukaemia

Radiotherapy
    Indication: Adult T-Cell Lymphoma / Leukaemia

Vincristine
    Dosage: (maximum 2 mg) on day 1 of 21 day cycle, (cycle 1-5)
    Indication: Adult T-Cell Lymphoma / Leukaemia

Zenapax
    Dosage: on days 7 and 14 on cycle 1 of 21 day cycle
    Indication: Adult T-Cell Lymphoma / Leukaemia

Other drugs received by patient: Cotrim; Itraconazole; Thiabendazole; Acyclovir



Possible Cyclophosphamide side effects in

Reported by a health professional (non-physician/pharmacist) from Japan on 2012-07-05

Patient:

Reactions: Neuropathy Peripheral, Interstitial Lung Disease, Neutropenia, Infection

Drug(s) suspected as cause:
Cyclophosphamide
    Indication: B-Cell Lymphoma

Doxorubicin HCL
    Indication: B-Cell Lymphoma

Neupogen
    Indication: B-Cell Lymphoma

Prednisolone
    Indication: B-Cell Lymphoma

Rituximab
    Dosage: 6 doses-2 days prior to each cycle of chop
    Indication: B-Cell Lymphoma

Vincristine
    Indication: B-Cell Lymphoma



Possible Cyclophosphamide side effects in

Reported by a physician from United States on 2012-07-05

Patient:

Reactions: Fatigue, Central Nervous System Haemorrhage, Erythema Multiforme, Dyspnoea, Stomatitis, Vomiting, Gastrointestinal Toxicity, Nausea, Condition Aggravated, Rash, Haematotoxicity, Pulmonary Haemorrhage, Tumour Lysis Syndrome, Diarrhoea, Respiratory Failure, Neurological Symptom, Infection

Adverse event resulted in: death

Drug(s) suspected as cause:
Cyclophosphamide
    Dosage: for 5 days in cycle 1
    Indication: Burkitt's Lymphoma

Cyclophosphamide
    Dosage: days 1-5 during cycle 3,5 and 7

Cyclophosphamide
    Dosage: for 5 days in cycle 1
    Indication: Burkitt's Leukaemia

Cyclophosphamide
    Dosage: days 1-5 during cycle 3,5 and 7

Cytarabine
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Cytarabine
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Dexamethasone Sodium Phosphate
    Dosage: on days 1-5 of cycle 2,4 and 6

Dexamethasone Sodium Phosphate
    Dosage: on days 1-5 of cycle 2,4 and 6

Dexamethasone Sodium Phosphate
    Dosage: on days 1-5 of cycle 3,5 and 7
    Indication: Burkitt's Leukaemia

Dexamethasone Sodium Phosphate
    Dosage: on days 1-5 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Doxorubicin HCL
    Dosage: on days 4 and 5 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Doxorubicin HCL
    Dosage: on days 4 and 5 of cycle 3,5 and 7
    Indication: Burkitt's Leukaemia

Etoposide
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Etoposide
    Dosage: on days 4 and 5 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Ifosfamide
    Dosage: on days 1-5 in cycle 2,4 and 6
    Indication: Burkitt's Lymphoma

Ifosfamide
    Dosage: on days 1-5 in cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Methotrexate
    Dosage: on day 1 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Methotrexate
    Dosage: on day 1 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Methotrexate
    Dosage: on day 1 of cycle 3,5 and 7

Methotrexate
    Dosage: on day 1 of cycle 2,4 and 6

Prednisone
    Dosage: for 7 days in cycle 1
    Indication: Burkitt's Lymphoma

Prednisone
    Dosage: for 7 days in cycle 1
    Indication: Burkitt's Leukaemia

Rituximab
    Dosage: on day 8 from cycle 3 to 7

Rituximab
    Dosage: on day 8 from cycle 3 to 7

Rituximab
    Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
    Indication: Burkitt's Leukaemia

Rituximab
    Dosage: day 8 on cycle 2; doage increased to 375 mg/m2 on day 10 and 12
    Indication: Burkitt's Lymphoma

Vincristine
    Dosage: on day 1 of cycle 3,5 and 7
    Indication: Burkitt's Lymphoma

Vincristine
    Dosage: on day 1 of cycle 2,4 and 6

Vincristine
    Dosage: on day 1 of cycle 3,5 and 7

Vincristine
    Dosage: on day 1 of cycle 2,4 and 6
    Indication: Burkitt's Leukaemia

Other drugs received by patient: Filgrastim; Unknown Medication; Leucovorin Calcium



 Page 1   Next >>

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017